{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:55:13Z","timestamp":1767848113253,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1038\/ncponc0899","type":"journal-article","created":{"date-parts":[[2007,7,27]],"date-time":"2007-07-27T13:28:46Z","timestamp":1185542926000},"page":"491-495","source":"Crossref","is-referenced-by-count":39,"title":["Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant"],"prefix":"10.1038","volume":"4","author":[{"given":"Taofeek","family":"Owonikoko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounzer","family":"Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Balassanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasios","family":"Raptis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFncponc0899_CR1","first-page":"801","volume":"17","author":"AN Bekassy","year":"1996","unstructured":"Bekassy AN et al. (1996) Granulocytic sarcoma after allogeneic bone marrow transplantation: a retrospective European multicenter survey. Acute and Chronic Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 17: 801\u2013808","journal-title":"Bone Marrow Transplant"},{"key":"BFncponc0899_CR2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/(SICI)1099-1069(199906)17:2<45::AID-HON641>3.0.CO;2-6","volume":"17","author":"WY Au","year":"1999","unstructured":"Au WY et al. (1999) Extra-medullary relapse of leukemia following allogeneic bone marrow transplantation. Hematol Oncol 17: 45\u201352","journal-title":"Hematol Oncol"},{"key":"BFncponc0899_CR3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1532\/IJH97.04195","volume":"82","author":"GJ Ruiz-Arguelles","year":"2005","unstructured":"Ruiz-Arguelles GJ et al. (2005) Extramedullary leukemic relapses following hematopoietic stem cell transplantation with nonmyeloablative conditioning. Int J Hematol 82: 262\u2013265","journal-title":"Int J Hematol"},{"key":"BFncponc0899_CR4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bmt.1701319","volume":"22","author":"DR Simpson","year":"1998","unstructured":"Simpson DR et al. (1998) High incidence of extramedullary relapse of AML after busulfan\/cyclophosphamide conditioning and allogeneic stem cell transplantation. Bone Marrow Transplant 22: 259\u2013264","journal-title":"Bone Marrow Transplant"},{"key":"BFncponc0899_CR5","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/10428190500057700","volume":"46","author":"IO Kara","year":"2005","unstructured":"Kara IO et al. (2005) Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone. Leuk Lymphoma 46: 1081\u20131084","journal-title":"Leuk Lymphoma"},{"key":"BFncponc0899_CR6","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/sj.leu.2403523","volume":"18","author":"SJ Choi","year":"2004","unstructured":"Choi SJ et al. (2004) Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia 18: 1789\u20131797","journal-title":"Leukemia"},{"key":"BFncponc0899_CR7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ajh.20421","volume":"81","author":"L Potenza","year":"2006","unstructured":"Potenza L et al. (2006) Isolated extramedullary relapse after autologous bone marrow transplantation for acute myeloid leukemia: case report and review of the literature. Am J Hematol 81: 45\u201350","journal-title":"Am J Hematol"},{"key":"BFncponc0899_CR8","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/sj.bmt.1704223","volume":"32","author":"KH Lee","year":"2003","unstructured":"Lee KH et al. (2003) Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course. Bone Marrow Transplant 32: 835\u2013842","journal-title":"Bone Marrow Transplant"},{"key":"BFncponc0899_CR9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1126\/science.272.5258.60","volume":"272","author":"EC Butcher","year":"1997","unstructured":"Butcher EC et al. (1997) Lymphocyte homing and homeostasis. Science 272: 60\u201366","journal-title":"Science"},{"key":"BFncponc0899_CR10","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nm915","volume":"9","author":"M Edinger","year":"2003","unstructured":"Edinger M et al. (2003) CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9: 1144\u20131450","journal-title":"Nat Med"},{"key":"BFncponc0899_CR11","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2141.2005.05872.x","volume":"132","author":"AM Tsimberidou","year":"2006","unstructured":"Tsimberidou AM et al. (2006) The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol 132: 398\u2013409","journal-title":"Br J Haematol"},{"key":"BFncponc0899_CR12","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","volume":"104","author":"RA Larson","year":"2005","unstructured":"Larson RA et al. (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104: 1442\u20131452","journal-title":"Cancer"},{"key":"BFncponc0899_CR13","first-page":"1490","volume":"7","author":"PF Bross","year":"2001","unstructured":"Bross PF et al. (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7: 1490\u20131496","journal-title":"Clin Cancer Res"},{"key":"BFncponc0899_CR14","doi-asserted-by":"crossref","unstructured":"Burnett AK et al. (2006) The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1,115 patients in the MRC AML15 trial [abstract #13]. Blood 108 (Suppl)","DOI":"10.1182\/blood.V108.11.13.13"},{"issue":"Suppl","key":"BFncponc0899_CR15","doi-asserted-by":"crossref","first-page":"S7164","DOI":"10.1158\/1078-0432.CCR-1004-0018","volume":"11","author":"E Roman","year":"2005","unstructured":"Roman E et al. (2005) Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clin Cancer Res 11 (Suppl): S7164\u2013S7170","journal-title":"Clin Cancer Res"},{"key":"BFncponc0899_CR16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.bmt.1703602","volume":"30","author":"AAD Cohen","year":"2002","unstructured":"Cohen AAD et al. (2002) Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant 30: 23\u201328","journal-title":"Bone Marrow Transplant"},{"key":"BFncponc0899_CR17","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1080\/1042819042000219485","volume":"45","author":"PP Piccaluga","year":"2004","unstructured":"Piccaluga PP et al. (2004) Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas. Leuk Lymphoma 45: 1791\u20131795","journal-title":"Leuk Lymphoma"}],"container-title":["Nature Clinical Practice Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncponc0899.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc0899","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc0899.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T03:18:31Z","timestamp":1708139911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncponc0899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["BFncponc0899"],"URL":"https:\/\/doi.org\/10.1038\/ncponc0899","relation":{},"ISSN":["1743-4254","1743-4262"],"issn-type":[{"value":"1743-4254","type":"print"},{"value":"1743-4262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}